SearchCME LoginCE Login Show Cart
NACE: National Association For Continuing Education 866-266-6223 9a am to 5 pm EST Mon-Fri
CME Course Description
   
Login to view
Course Activities.

CME Live Conversations in PC

Go Back




Title
: Emerging Challenges in Primary Care 2017 Miami, FL
Activity/Course #:
: 04.29.17PC
Cost:
: Free
Release/Start Date:
: Apr 29 2017
Expiration Date:
: Apr 29 2017
Topics:
: Primary Care Medicine
Target Audience:
: Primary Care Providers
Format:
: Live EC Primary Care
Estimated Time To Complete CME Activity:
: 6.0 hours
Credit(s):
: 6.0 AMA PRA Category I Credit(s)
6.0 AANP Contact hour(s)
Hardware/Software Requirements:
(Chrome not supported at this time)

Saturday, April 29, 2017
Hilton Miami Airport

5101 Blue Lagoon Drive

Miami, FL 33126
(305) 262-1000

Registration Fee
There is no registration fee for this activity.

Special Accommodations

NACE fully complies with the legal requirements of the Americans with Disabilities Act. Any activity registrant who feels s/he may need accommodations based on the impact of a disability should contact NACE to discuss your specific need.

Event Parking

A discounted self parking rate of $5.00 per vehicle is available at the hotel.

Hotel Guest Rooms

NACE has reserved a sleeping room rate of $159 per night at the Hilton Miami Airport. To reserve your room at this rate call (305) 262-1000 and ask for the NACE group rate by April 5, 2017.

Program Summary

Primary care providers face complex challenges everyday in their busy practices. With rapid changes in medicine, staying informed about new developments can be equally challenging. Our goal in this CME activity is to help you hone your skills in the diagnosis and management of patients with varied conditions you are likely encountering in your practice.

We have recruited a faculty of well-known thought leaders and experienced teachers who, as clinicians themselves, understand the challenges you face every day as a primary care provider. Our faculty will be at your disposal to provide evidence-based science, current treatment guidelines, discuss challenging cases, and provide answers for you that can ultimately lead to better health care for your patients. The presentations will include several interactive cases and discussion sessions to keep you actively learning.

Please join us and become an active participant in this one-day learning community of your peers.

Learning Objectives
At the conclusion of this program, participants should be able to:

  1. List 2017 Quality Measures for the use of statin therapy for the prevention and treatment of cardiovascular disease; Explain the role of anti-PCSK9 monoclonal antibody therapy in LDL-C reduction to achieve cardiovascular risk reduction; Discuss ACC guidelines on the role of non-statin therapies in the management of atherosclerotic cardiovascular disease; Employ guideline-directed treatment strategies for primary and secondary prevention of cardiovascular disease in high-risk patient populations.

  2. Describe the role of the kidney in glucose metabolism in health and disease; Review the physiologic effects and clinical efficacy of SGLT-2 therapy in various patient populations; Review emerging data on possible renal and macrovascular effects of evidence-based diabetes treatment options; Integrate the impact of treatment decisions on postprandial hyperglycemia and risk of hypoglycemia.

  3. Discuss the role of postprandial hyperglycemia in the pathogenesis of diabetic complications; Incorporate GLP-1 RA therapy into practice to reduce post-prandial hyperglycemia and decrease glycemic variability; Compare GLP-1 RAs for glycemic efficacy and differential impact on postprandial glycemic control; Discuss various GLP-1 RA combination strategies with or as a possible alternative to basal insulin in the diabetic patient not at glycemic target.

  4. Describe the typical clinical presentation of a patient with possible idiopathic pulmonary fibrosis (IPF); Discuss the diagnostic approach to a patient with suspected IPF; Discuss and contrast the available pharmacotherapeutic options for patients with IPF; Discuss and contrast the available nonpharmacotherapeutic options for patients with IPF.

  5. Discuss the pathophysiology of alpha1-antitrypsin deficiency (AATD); Utilize appropriate screening for AATD; Incorporate AATD testing into routine chronic obstructive pulmonary disease (COPD) management algorithms; Discuss treatment options for AATD and latest GOLD guideline recommendations.
 
Agenda*

7:30-8:00

  Continental Breakfast and Registration
8:00-8:10   Welcome Remarks
Gregg Sherman, MD
8:10-9:20  

New Agents, New Options, and Expanded Potential In Lipid Management: Integrating The Data Into Practice
Peter P. Toth, MD, PhD, FCCP, FAHA, FESC, FACC

9:20-10:30   Integrating Data on Macrovascular and Microvascular Outcomes into Diabetes Management: Evolving Treatment Strategies
Richard Pratley, MD
10:30-10:50   Break
10:50-12:00   GLP-1 Receptor Agonists: New Insights and New Strategies for Successful Long-Term Diabetes Management
Richard
Pratley, MD

12:00-1:00  

Lunch

1:00-2:10   Idiopathic Pulmonary Fibrosis: Defining the Role of the Primary Care Clinician in Diagnosis and Therapy
Franck Rahaghi, MD, MHS, FCCP
2:10-3:20  

Demystifying A1AT Deficiency and COPD: A Practical Guidance for Clinicians
Franck Rahaghi, MD, MHS, FCCP

   3:20-3:30 Summary of Key Points and Closing Remarks
 
*Agenda subject to change.
 
Faculty
Richard Pratley, MD
Senior Investigator and Diabetes Program Head
Translational Research Institute for Metabolism and Diabetes
Research and Education Director, Florida Hospital Diabetes Institute
Orlando, FL
 
Franck Rahaghi, MD, MHS, FCCP
Director of Advanced Lung Disease Clinic
Director, Pulmonary Hypertension Clinic
Head of Alpha-1 Foundation Clinical Resource Center
Cleveland Clinic Florida
Weston, FL
 
Peter P. Toth, MD, PhD, FCCP, FAHA, FESC, FACC
Director of Preventative Cardiology
CGH Medical Center
Sterling, IL
Professor of Clinical Family and Community Medicine
University of Illinois College of Medicine
Peoria, IL
 
Planning Committee
Gregg Sherman, MD
Chief Medical Officer/Course Director
National Association for Continuing Education
Plantation, FL


Sheila Lucas, CWEP
Activity Director
National Association for Continuing Education

Plantation, FL

Michelle Frisch, MPH, CHCP
National Association for Continuing Education

Plantation, FL

Cassandra A. McCullough, MBA

Chief Executive Officer

Association of Black Cardiologists

New York, NY

Harvey C. Parker, Ph.D., CHCP
National Association for Continuing Education

Plantation, FL

Sponsored and Certified By
National Association for Continuing Education & Association of Black Cardiologists, Inc.
Accreditation Designation Statement
The Association of Black Cardiologists, Inc. is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

The Association of Black Cardiologists, Inc. designates this live activity for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

The National Association for Continuing Education is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

The National Association for Continuing Education designates this live activity for a maximum of 5.0 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

National Association for Continuing Education is approved as a provider of nurse practitioner continuing education by the American Association of Nurse Practitioners. AANP Provider Number 121222. This program has been approved for 6 contact hours of continuing education (which includes 3.0 pharmacology hours).
Faculty Disclosure Policy
Policy on Faculty and Provider Disclosure: It is the policy of the accredited providers to ensure fair balance, independence, objectivity and scientific rigor in all activities. All faculty participating in CME activities sponsored by the accredited providers are required to present evidence-based data, identify and reference off-label product use and disclose all relevant financial relationships. Faculty disclosure will be provided in the activity materials.
Commercial Support
Emerging Challenges in Primary Care: 2017 is supported by an independent educational grant from Boehringer Ingelheim Pharmaceuticals, Inc.; an independent educational grant from Boehringer Ingelheim Pharmaceuticals, Inc. and Lilly USA, LLC.; an educational grant from Grifols; an educational grant from Sanofi US and Regeneron Pharmaceuticals; and an educational grant from Lilly. For further information concerning Lilly grant funding visit www.lillygrantoffice.com.